biotechnology

Avalo Therapeutics prices $375M offering of 19.73M shares at $17.75 each to fund Phase 3 development of hidradenitis suppurativa treatment abdakibart, closing May 7, 2026.

Adaptive Biotechnologies COO Julie Rubinstein sold 19,037 shares worth $271,000 under a pre-planned trading arrangement, retaining substantial equity as the biotech firm posts strong 55% revenue growth.

Hemab Therapeutics raised $346.7M in upsized IPO, pricing 19.3M shares at $18 with full underwriter exercise.

Zealand Pharma to hold Extraordinary General Meeting May 26 to vote on Board candidate Camilla Sylvest; Q1 results presented May 7.

Hemab Therapeutics prices $301.5M IPO at $18/share, listing on Nasdaq as $COAG starting May 1, 2026.

Eli Lilly beat Q1 earnings expectations and raised full-year guidance, driven by blockbuster demand for weight-loss drugs Mounjaro and Zepbound.

Vaccinex released 2025 financial results while launching Phase 2b Alzheimer's study, advancing its antibody therapy pipeline for neurodegenerative diseases and cancer.

QXO to acquire TopBuild for $17B. Multiple companies face activist pressure for strategic reviews. Tech and pharma close major deals.

Regeneron offers gene therapy Otarmeni free and Praluent at lower pricing in exchange for tariff relief and exemption from future pricing mandates.

Zealand Pharma discloses insider share transactions by executives and board members, providing investors transparency into management's confidence in the company's prospects.

JATT II Acquisition Corp closed a $60M IPO on NASDAQ under ticker $JATT, priced at $10/share, focusing on healthcare and biotech combinations via data-driven discovery approaches.

Kailera Therapeutics raises $718.8M in IPO at $16/share as obesity care biotech enters public markets with strong underwriter demand.

Zealand Pharma discloses insider transactions by executives and board members, fulfilling regulatory requirements and signaling management confidence in biotech operations.

$ADPT's President/COO sold $826K in shares via option exercise while retaining 408K shares. MRD revenue grew 46%; Medicare coverage expansion supports growth outlook.

Clinical-stage biotech Kailera prices IPO at $16/share, raising $625M. Company debuts on Nasdaq ($KLRA) April 17 with positive Phase 2 obesity drug data.

Great American Food Chain completes GreenMatter Biotech merger, names Joe Wicker Jr. CEO. Plant-based materials company generated $2.5M 2025 revenue, gains public market access.

Spyre Therapeutics prices $403M stock offering at $62/share with 6.5M shares, expected to close April 16, 2026. Prominent underwriters include Goldman Sachs and Jefferies.

Allogene prices 87.5M shares at $2.00 each, raising $175M gross proceeds for clinical trials and R&D operations.

U.S. stock futures rise on Iran deal optimism; Sana Biotech surges 20% on Mayo Clinic partnership while energy inflation concerns persist.

Clinical-stage biotech Spyre Therapeutics launches $300M public offering to fund inflammatory bowel disease drug development, with major investment banks leading.